(631) 444-2600
MEENAKSHI SINGH MD
For Appointments:
(631) 444-2600
ANATOMICAL PATHOLOGY
BREAST CANCER
BREAST PATHOLOGY
CANCER
CYTOPATHOLOGY
FINE NEEDLE BIOPSY WITH INTERPRETATION
GYNECOLOGIC PATHOLOGY
GYNECOLOGICAL PATHOLOGY
OVARIAN CANCER
PATHOLOGY
PATHOPHYSIOLOGY
SURGICAL PATHOLOGY
1199NBF
AETNA
AFFINITY HEALTH PLAN
BEECH STREET
CIGNA GREAT WEST HEALTHCARE
CIGNA HMO
CIGNA PPO
EMPIRE BLUE CROSS HMO
EMPIRE BLUE CROSS OTHER PLANS
EMPIRE BLUE CROSS PPO
EMPIRE BLUE CROSS SENIOR PLAN
FIDELIS CARE NEW YORK
GHI CBP
GHI HMO
HEALTHFIRST
HIP
ISLAND GROUP ADMINISTRATION
MAGNACARE
MEDICAID
MEDICARE
MULTIPLAN
MULTIPLAN PHCS
MULTIPLAN SAVILITY
NEIGHBORHOOD HEALTH PLAN
NO FAULT
SUFFOLK HEALTH PLAN
UNITED HEALTHCARE
UNITED OXFORD FREEDOM PLAN
US FAMILY HEALTH PLAN
VYTRA (except SMART START)
WORKERS COMP
Education & Training
- Medical Degree:
- Christian Medical College, India
- Residency:
- Pathology, University of Colorado & Health Sciences Center, CO
- Fellowship:
-
Surgical Pathology, University of Iowa Hospitals & Clinics, IA
Academic & Other
- Teaching Activity:
- Pathology
- Year Appointed at
Stony Brook:
- 2008
2008 Vice Chair of Anatomic Pathology, Dept. of Pathology, Stony Brook University, School of Medicine
2007 & 2008 Best Doctors in America
2008 Who's Who in America
2008 Recognition for outstanding leadership by the Histology Laboratory, School of Medicine, University of Colorado, Denver
2008 Certificate of Excellence in honor of outstanding performance, dedication and high standards in Gynecologic Oncology Pathology by the Chief of Gynecologic Oncology, University of Colorado Hospital
1999-2006 Colorado Society of Clinical Pathologists' award for service, dedication, leadership and outstanding achievement
2004-05 Excellence in teaching Pathology 6000, The University of Colorado Medical School Class of 2007
- Clinical Practice Began:
- 1981
Locations
-
PATHOLOGY
UNIVERSITY MEDICAL CENTER,
NICOLLS ROAD,
STONY BROOK,
NY 11794-7025.
Selected Publications
1. Singh M, Speolstra NS, Jean A, Howe EN, Shroyer KS, Torkko KC, Clark HR, Darling D, Horwitz KB, Broaddus RR and Richer JK. ZEB 1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Modern Pathology 2008 21(7):912-23, Epub May 16, 2008.
2. Leslie KK, Walter SA, Stephens JK, Thompson C, Singh, M. Effect of Tamoxifen on endometrial histology, hormone receptors and cervical cytology: a prospective study with follow up. Appl Immunohistochem Mol Morph 2007 Sept; 15(3):284-293.
3. Singh, M., Zaino, R., Brunetto, V., and Leslie, K.K. Relationship of Estrogen Receptor-a and Progesterone Receptors A and B to clinical outcome: A Gynecologic Oncology Group study. Gynecologic Oncology 2007, May 24; [Epub ahead of print]. 106(2):325-33.
4. Balmer N, Richer J, Spoelstra N, Lyle PL, Torkko K, Singh M. Steroid receptor coactivator AIB 1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinico-pathologic parameters and biomarkers. Modern Pathology Sep 15, 2006 [Epub ahead of print]; Modern Pathology 2006:19;1593-1605.
5. Grupka N, Parnes MB, Bloom C, Singh M. Expression of retinoblastoma protein in breast cancer metastases to sentinel nodes: comparison with p16INK4a as a possible marker for the presence of metastases in additional axillary nodes. Appl Immunohistochem Mol Morphol 2006;14 (1):63-70.
6. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006 Aug 25; [Epub ahead of print] Cancer. 2006 Oct 25;108(5):324-30
7. Singh M, Capocelli KE, Marks JL, Schleicher RB, Finlayson CA, Seligman PA. The expression of vascular endothelial growth factor and the proliferation marker MIB-1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer. App Imm & Mol Morph June 2005; 13:147-156.
8. Singh M, Parnes MB, Spoelstra N, Bleile MJ, Robinson WA. p16 expression in sentinel nodes with metastatic breast carcinoma: a marker for developing triaging strategies for axillary node dissection and a marker for poor prognosis. Human Pathol 2004; 35(12):1524-30.
9. Singh M, Bleile MJ, Shroyer LA, Heinz D, Jarboe EA, Shroyer KR. Analysis of Survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol. 2004 Dec; 12(4):296-304.
10. Grupka N, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Arch of Path & Lab Med. 2004; 128: 974-9. Front cover of the Journal.
11. Lear-Kaul KC, Yoon H-R, Kleinschmidt-DeMasters BK, McGavran L, Singh M. HER/2neu status in breast cancer metastases to the central nervous system. Arch Path & Lab Med 2003; 127:1451-7.
12. Singh M, McGinley JN, Thompson HJ. A comparison of the histopathology of pre-malignant and malignant mammary gland lesions induced in sexually immature rats with those occurring in the human. Laboratory Investigation 80(2): 221-231, 2000.
Personal Statement
There are 700 + physicians and other health care providers practicing within 18 different clinical entities, or specialty groups that are affiliated with Stony Brook University Physicians (SBU Physicians). Together, these providers offer patients of all ages a comprehensive range of high quality medical services, from primary care to advanced specialty care. The physicians and health care professionals affiliated with SBU Physicians are committed to excellence in service and leadership in clinical care. In their capacity as faculty of the Stony Brook University School of Medicine, they also educate medical students, interns, residents and fellows in many specialties and sub-specialties, and engage in research and clinical trials that help to advance the science of medicine.
These physicians and health care professionals are committed to excellence in service and leadership in clinical care for their patients. SBU Physicians supports and coordinates this mission and maintains this website for patients, physicians and staff.
